News

Video

Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study

Author(s):

Michael Wang, MD

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Related Videos
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study
Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis
A Phase 0/1 ‘trigger’ trial of BDTX-1535 in recurrent high-grade glioma (HGG) patients with EGFR alterations or fusions
Tycel Phillips, MD, MPH
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Related Content
Anita Kumar, MD
June 15th 2024

Zanubrutinib Plus Obinutuzumab/Venetoclax Is Safe, Elicits Responses in Older Patients With Untreated MCL

Lori A. Leslie, MD
February 27th 2023

FDA Approval Insights: Pirtobrutinib in MCL

Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Joshua Brody, MD
December 8th 2022

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

MCL | Image Credit: ©freshidea - stock.adobe.com
May 20th 2024

Adding Ibrutinib to Chemoimmunotherapy Induction Improves FFS in Younger MCL

Gulrayz Ahmed, MD, the Medical College of Wisconsin
May 14th 2024

Retrospective Analysis Shows Efficacy and Safety of CAR T-Cell Therapy in MCL With SCNS